



**FOR IMMEDIATE RELEASE:**

## **EyeGate Pharma Adds Drug Development and Delivery Expert, Praveen Tyle, to its Board of Directors**

**Waltham, MA, – June 9, 2008** – EyeGate Pharma, a privately held, specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics into the front and back of the eye to treat serious ocular diseases, today announced the appointment of Praveen Tyle, Ph.D., as a member of its Board of Directors. Dr. Tyle is currently Chief Scientific Officer, and Corporate Vice President, Research & Development at Bausch & Lomb, a global healthcare company dedicated to perfecting vision and enhancing life for consumers around the world.

Stephen From, President and Chief Executive Officer of EyeGate Pharma, commented, “Dr. Tyle has vast experience in ophthalmic drug delivery and formulation, and is a strong addition to our distinguished Board and complements our existing senior leadership team. EyeGate is moving forward with clinical trials using the EyeGate® II Ocular Delivery System with our lead clinical compound EGP-437, a proprietary formulation of a well studied ophthalmic corticosteroid. This program is scheduled to enter Phase I / II clinical development initially for severe acute uveitis in the near future, followed by dry eye later in 2008. This is an exciting time for EyeGate and we welcome Dr. Tyle to the Board.”

With more than twenty years of industry experience, Dr. Tyle also has extensive, global regulatory, business development and product in-licensing / out-licensing experience. In his current position, Dr. Tyle focuses in areas including vision care (lens and lens care), pharmaceuticals (prescription, OTC, generics, nutritionals), and surgical (refractive and cataract). He is also responsible for all of the company's preclinical development programs, product development efforts, and clinical, medical and regulatory affairs and quality assurance.

Previously, Dr. Tyle was Group Vice President, Pharmaceutical Sciences and Manufacturing at Biovail Corporation. He began his professional career as a formulations research chemist in drug delivery research with American Cynamid Company (now Wyeth), moving on to executive leadership and scientific positions with Sandoz Pharmaceuticals (now Novartis), Agouron Pharmaceuticals (now Pfizer) and Aronex Pharmaceuticals (now Antigenics). In 1999, Dr. Tyle was named Vice President – Pharmaceutical Sciences, U.S., Pharmacia & Upjohn (now Pfizer).

-more-

Dr. Tyle holds academic appointments as an Adjunct Professor of Ophthalmology at the University of Rochester Eye Institute, as well as an Adjunct Professor of Pharmacy at the University of Rhode Island, Howard University, Washington DC, and at the University of Houston, Texas. He is editor of seven books about drug development, he holds several patents and is the author of more than 125 technical and scientific papers and presentations.

Dr. Tyle holds a Doctorate in Pharmaceutics and Pharmaceutical Chemistry from The Ohio State University and a B. Pharm (honors) from the Institute of Technology, Banaras Hindu University, India.

### **About EyeGate Pharma**

EyeGate Pharma recently initiated of a Phase I clinical study designed to assess the safety and tolerability of the non-invasive EyeGate® II Ocular Drug Delivery System and plans to initiate Phase 2 clinical trials in the first half 2008 in uveitis and later in dry eye. EyeGate was founded in 1999 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. EyeGate's transscleral (white membrane of the eye) iontophoresis delivery platform, the EyeGate® II Delivery System, was developed to safely deliver a wide range of therapeutics to both the anterior (front) and posterior (back) chambers of the eye. For more information please visit [www.eyegatepharma.com](http://www.eyegatepharma.com).

# # #

### **IR/PR Contact:**

Bryan Murphy or Tim Allison  
LaVoie Group  
978-745-4200 X105 or X102  
[bmurphy@lavoiegroup.com](mailto:bmurphy@lavoiegroup.com) or  
[tallison@lavoiegroup.com](mailto:tallison@lavoiegroup.com)